Regeneron (REGN) Valuation Check After Lynozyfic Trial Success and New Gene Writing Collaboration

Regeneron Pharmaceuticals (REGN) has caught investors attention after unveiling promising Phase 1/2 data for its multiple myeloma candidate Lynozyfic, along with fresh progress in gene writing and high profile scientific conference appearances.

See our latest analysis for Regeneron Pharmaceuticals.

Those Lynozyfic results and the new gene writing collaboration have landed against a strong backdrop, with Regeneron’s 90 day share price return of 26.66 percent pointing to building momentum. The five year total shareholder return of 54.2 percent shows longer term holders have already been rewarded.

If Regeneron’s pipeline has caught your eye, it is worth seeing what else is brewing across innovative drug makers by exploring healthcare stocks.

Yet with shares up double digits in three months and trading only slightly below analyst targets, is Regeneron still undervalued on its pipeline firepower, or is the market already pricing in the next wave of growth?

Most Popular Narrative: 4% Undervalued

With the narrative fair value sitting modestly above Regeneron’s recent 749.79 dollar close, the story leans toward patient upside driven by durable earnings power.

The fair value estimate has risen slightly to approximately 781 dollar per share from about 768 dollar, reflecting higher projected earnings power. The net profit margin has improved to about 30.23 percent from approximately 28.98 percent, incorporating expectations for better operating leverage.

Read the complete narrative.

Want to see what justifies paying up from here? This narrative quietly leans on steadier growth, fatter margins, and a richer future earnings multiple. Curious which assumptions really move that fair value line? Dive in to uncover the numbers behind this call.

Result: Fair Value of $781.13 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this upside view could unravel if Eylea headwinds deepen or late stage pipeline bets disappoint, undermining the premium multiple now implied.

Find out about the key risks to this Regeneron Pharmaceuticals narrative.

Build Your Own Regeneron Pharmaceuticals Narrative

If you see things differently or want to test your own assumptions, you can build a personalized view of Regeneron’s prospects in just minutes, Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Regeneron Pharmaceuticals.

Looking for more investment ideas?

Before you move on, lock in a stronger watchlist by scanning focused sets of opportunities that could sharpen your next move beyond Regeneron.

• Supercharge your hunt for value by targeting companies trading below their cash flow potential with these 910 undervalued stocks based on cash flows.
• Ride powerful secular trends by zeroing in on innovators reshaping markets through these 26 AI penny stocks.
• Strengthen your income stream by pinpointing reliable payers using these 13 dividend stocks with yields > 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com